We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PBI:NYSEPitney Bowes Inc. Analysis

Data as of 2026-04-23 - not real-time

$15.37

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Pitney Bowes (PBI) is trading at $15.37, comfortably above its 20‑day ($12.02), 50‑day ($11.11) and 200‑day ($10.95) simple moving averages, and the MACD line sits in bullish territory (+1.02 vs signal +0.60). Technical momentum is strong, reinforced by an increasing volume trend and an RSI of 91 that signals the stock is overbought. Recent news highlights a “strong preliminary Q1 2026 result” and an upward revision of full‑year guidance, while the dividend yield of 2.37% with a 35.7% payout ratio adds income appeal. These factors combine to create short‑term upside potential despite a lofty price.
On the fundamental side, revenue is down 7.5% YoY, the company carries $2.16 B of debt and reports a negative book value per share (-$5.32), leading to a price‑to‑book ratio of -2.89. The discounted cash‑flow model suggests a fair value near $3.56, implying a downside of roughly 17%, and the 30‑day volatility of 43.6% underscores a high risk environment. While the dividend appears sustainable given positive operating cash flow, the combination of earnings compression, high leverage, and overvaluation raises concerns for medium‑ and long‑term investors.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish technical indicators (price above SMAs, bullish MACD)
  • Strong Q1 preliminary results and raised guidance
  • Increasing volume and attractive dividend yield

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Overvaluation relative to DCF fair value
  • Revenue contraction and high debt load
  • Sustainable dividend but negative book value

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Negative book value and high leverage
  • DCF suggests substantial downside
  • Persistent revenue decline and elevated volatility

Key Metrics & Analysis

Financial Health

Revenue Growth-7.50%
Profit Margin7.65%
P/E Ratio18.3
ROA7.22%
P/B Ratio-2.9
Op. Cash Flow$383.3M
Free Cash Flow$177.0M
Industry P/E31.4

Technical Analysis

TrendBullish
RSI91.7
Support$10.79
Resistance$15.57
MA 20$12.02
MA 50$11.11
MA 200$10.95
MACDBullish
VolumeIncreasing
Fear & Greed Index87.27

Valuation

Fair Value$3.56
Target Price$12.70
Upside/Downside-17.37%
GradeOvervalued
TypeBlend
Dividend Yield2.37%

Risk Assessment

Beta1.09
Volatility43.65%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.